Thread by @manishlalwani9

Q-Line Biotech SME IPO opens today.

I recently visited their Lucknow manufacturing facility and spent time understanding the business, management and industry dynamics first-hand.

Some notes & observations from the ground 👇(1/10)

1/ Q-Line operates in the IVD (In Vitro Diagnostics) space — basically machines & reagents used in pathology labs.

Strong presence in Clinical Chemistry & Hematology with meaningful market share in India’s reagent market.

(2/10)

2/ A large part of the business currently comes from UP government hospital labs via promoter-linked POCT Group.

POCT handles end-to-end diagnostics operations while Q-Line supplies machines/reagents.

Overall group scale:
• POCT ~₹650 Cr
• Q-Line ~₹320 Cr
• Heidelco ~₹100 Cr

So, a big UP based healthcare group. (3/10)

3/ Interesting business economics:

• Instruments sold at low margins

• Reagents generate ~60–65% gross margins

• One machine can generate 8–10x its value over lifecycle through consumables

Classic razor-blade model with sticky recurring revenue.

(4/10)

4/ Biggest product to track: Selectra Pro M.

Originally sourced from Netherlands, now being manufactured domestically with no visible quality compromise while reducing costs materially vs imports.

This has now opened up reverse-export opportunities as well — an important long-term trigger.

(5/10)

5/ Current mix:

~52% manufacturing
~48% trading/imported products

Management’s focus is to steadily increase indigenous manufacturing over time.

Instrument sales seed future reagent revenue.

(6/10)

6/ Reagent business is the real cash engine.

FY25 reagent revenue was ~₹175 Cr.
~60–65% manufactured in-house.

Rapid kits (dengue, thyroid, pregnancy, Vitamin D etc.) are also scaling fast and have shorter working capital cycles.

(7/10)

7/ The new Lucknow facility is a key part of the story.
Management claims no major capex is now required to scale towards ~₹1,000 Cr revenue.

IPO proceeds are mainly for:
• Working capital
• Debt repayment

Meaning infra is largely already built.

8/ FY25 reported numbers:

• Revenue: ~₹320 Cr
• PAT: ~₹28 Cr

However PAT included a one-time extraordinary loss. Adjusted operating PAT is closer to ~₹45 Cr.

At IPO price, valuation comes around ~15–18x earnings depending on the basis used.

(8/10)

9/ Institutional participation is strong.

Names like Carnelian, Abakkus-linked participation and other known investors being present at IPO/pre-IPO stage adds credibility to the story.

(9/10)

10/ Risks involved and should be tracked:

• Heavy dependence on UP/POCT ecosystem
• Related-party concentration
• Negative operating cash flow historically
• IT proceedings disclosed in RHP
• SME liquidity risk post listing

(10/10)

Overall, I found Q-line Biotech an Interesting business with strong manufacturing ambition, but execution & diversification will be key from here.

Please note - Not an investment recommendation or IPO applying solicitation. Please do your own research. Just read of the company.